Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA/ChAd63 Malaria Vaccine Trial
NCT03341754Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NMRC-M3V-D-PfCAT and ChAd63-PfCAT in malaria (3 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Occurrence of Serious Adverse Events, Occurrence of Abnormal Physical Symptoms and 2 more. Started Sep 2018; status: completed.
02
Drugs
NMRC-M3V-D-PfCATChAd63-PfCAT
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03341754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341754.